Technical Analysis for LOXO - Loxo Oncology, Inc.
|Grade||Last Price||% Change||Price Change|
LOXO closed up 0.11 percent on Friday, January 18, 2019, on 1.46 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
|See historical LOXO trend table...|
|Date||Alert Name||Type||% Chg|
|Jan 8||New Uptrend||Bullish||0.52%|
|Jan 8||Volume Surge||Other||0.52%|
|Jan 8||Calm After Storm||Range Contraction||0.52%|
|Jan 8||Narrow Range Bar||Range Contraction||0.52%|
|Jan 8||NR7||Range Contraction||0.52%|
|Jan 8||NR7-2||Range Contraction||0.52%|
|Jan 8||Parabolic Rise||Strength||0.52%|
|Jan 8||Stochastic Reached Overbought||Strength||0.52%|
|Jan 8||Upper Bollinger Band Walk||Strength||0.52%|
|Jan 8||Inside Day||Range Contraction||0.52%|
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
Loxo Oncology, Inc., a development-stage company, develops targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its lead product candidate includes LOXO-101, an oral and selective inhibitor of tropomyosin receptor kinase, which is in a Phase I dose escalation trial for the treatment of patients with advanced solid tumor types, such as neuroblastoma and lung, thyroid, and breast cancers. The company is also developing a pipeline of additional product candidates targeting cancers driven by genetic alterations. Loxo Oncology, Inc. has a drug discovery collaboration agreement with Array BioPharma Inc. The company was founded in 2013 and is headquartered in Stamford, Connecticut.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more LOXO news...
|52 Week High||233.9|
|52 Week Low||85.21|
|200-Day Moving Average||160.822|
|50-Day Moving Average||162.0638|
|20-Day Moving Average||183.799|
|10-Day Moving Average||232.859|
|Average True Range||7.3999|
|Chandelier Exit (Long, 3 ATRs )||211.7003|
|Chandelier Exit (Short, 3 ATRs )||147.1997|
|Upper Bollinger Band||282.1117|
|Lower Bollinger Band||85.4863|
|Percent B (%b)||0.75|
|MACD Signal Line||20.0284|
|Market Cap||6.96 Billion|
|Num Shares||29.8 Million|
|Price-to-Earnings (P/E) Ratio||-55.86|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||234.01|
|Resistance 3 (R3)||233.98||233.79||233.93|
|Resistance 2 (R2)||233.79||233.66||233.80||233.90|
|Resistance 1 (R1)||233.64||233.58||233.55||233.67||233.87|
|Support 1 (S1)||233.30||233.32||233.21||233.33||233.13|
|Support 2 (S2)||233.11||233.24||233.12||233.10|
|Support 3 (S3)||232.96||233.11||233.08|
|Support 4 (S4)||232.99|